{"transactions":[{"id":892413,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T22:00:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":175000,"derivative":{"exercise_price":12.44,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001193125-26-059638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526059638/ownership.xml","form_type":"4"}},{"id":1252101,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-21T23:00:09.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":75000,"derivative":{"exercise_price":9.43,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-25-025031","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025025031/ownership.xml","form_type":"4"}},{"id":1252100,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-02-21T23:00:09.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest on an annual basis over four years."}],"balance_after":240990,"source":{"system":"sec-edgar","filing":"0000950170-25-025031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025025031/ownership.xml","form_type":"4"}},{"id":1621646,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-23T22:00:50.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":75000,"derivative":{"exercise_price":17.54,"expiration_date":"2034-02-22","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-019463","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024019463/ownership.xml","form_type":"4"}},{"id":1621645,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-23T22:00:50.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest on an annual basis over four years."}],"balance_after":203490,"source":{"system":"sec-edgar","filing":"0000950170-24-019463","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024019463/ownership.xml","form_type":"4"}},{"id":1660546,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-03T02:35:12.000Z","date":"2024-02-01","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on September 1, 2019, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on September 1, 2022."}],"balance_after":70331,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-010975","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024010975/ownership.xml","form_type":"4"}},{"id":1660545,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-03T02:35:12.000Z","date":"2024-02-01","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":16.18,"value":647200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165990,"source":{"system":"sec-edgar","filing":"0000950170-24-010975","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024010975/ownership.xml","form_type":"4"}},{"id":1660544,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-02-03T02:35:12.000Z","date":"2024-02-01","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":4.3,"value":172000.0,"ownership":{"direct":true},"balance_after":205990,"source":{"system":"sec-edgar","filing":"0000950170-24-010975","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024010975/ownership.xml","form_type":"4"}},{"id":1666208,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-31T00:00:04.000Z","date":"2024-01-29","kind":"exercise","planned":true,"acquired":false,"shares":26003,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares vested on September 1, 2019, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on September 1, 2022."}],"balance_after":110331,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":26003},"source":{"system":"sec-edgar","filing":"0000950170-24-009047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024009047/ownership.xml","form_type":"4"}},{"id":1666207,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-31T00:00:04.000Z","date":"2024-01-29","kind":"exercise","planned":true,"acquired":false,"shares":13997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":13997},"source":{"system":"sec-edgar","filing":"0000950170-24-009047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024009047/ownership.xml","form_type":"4"}},{"id":1666206,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-31T00:00:04.000Z","date":"2024-01-29","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":14.09,"value":563600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.54. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165990,"source":{"system":"sec-edgar","filing":"0000950170-24-009047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024009047/ownership.xml","form_type":"4"}},{"id":1666205,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-31T00:00:04.000Z","date":"2024-01-29","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":4.3,"value":172000.0,"ownership":{"direct":true},"balance_after":205990,"source":{"system":"sec-edgar","filing":"0000950170-24-009047","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024009047/ownership.xml","form_type":"4"}},{"id":1671794,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:00:05.000Z","date":"2024-01-23","kind":"exercise","planned":true,"acquired":false,"shares":21316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023."}],"balance_after":13997,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":21316},"source":{"system":"sec-edgar","filing":"0000950170-24-007032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024007032/ownership.xml","form_type":"4"}},{"id":1671793,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:00:05.000Z","date":"2024-01-22","kind":"exercise","planned":true,"acquired":false,"shares":14559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023."}],"balance_after":35313,"derivative":{"exercise_price":4.3,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":14559},"source":{"system":"sec-edgar","filing":"0000950170-24-007032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024007032/ownership.xml","form_type":"4"}},{"id":1671792,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-24T22:00:05.000Z","date":"2024-01-23","kind":"sale","planned":true,"acquired":false,"shares":21316,"price":12.46,"value":265597.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165990,"source":{"system":"sec-edgar","filing":"0000950170-24-007032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024007032/ownership.xml","form_type":"4"}},{"id":1671791,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-24T22:00:05.000Z","date":"2024-01-23","kind":"exercise","planned":true,"acquired":true,"shares":21316,"price":4.3,"value":91658.8,"ownership":{"direct":true},"balance_after":187306,"source":{"system":"sec-edgar","filing":"0000950170-24-007032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024007032/ownership.xml","form_type":"4"}},{"id":1671790,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-24T22:00:05.000Z","date":"2024-01-22","kind":"sale","planned":true,"acquired":false,"shares":4125,"price":12.02,"value":49582.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":165990,"source":{"system":"sec-edgar","filing":"0000950170-24-007032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024007032/ownership.xml","form_type":"4"}},{"id":1671789,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-24T22:00:05.000Z","date":"2024-01-22","kind":"sale","planned":true,"acquired":false,"shares":14559,"price":12.18,"value":177328.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":170115,"source":{"system":"sec-edgar","filing":"0000950170-24-007032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024007032/ownership.xml","form_type":"4"}},{"id":1671788,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-24T22:00:05.000Z","date":"2024-01-22","kind":"exercise","planned":true,"acquired":true,"shares":14559,"price":4.3,"value":62603.7,"ownership":{"direct":true},"balance_after":184674,"source":{"system":"sec-edgar","filing":"0000950170-24-007032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024007032/ownership.xml","form_type":"4"}},{"id":2002749,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-21T23:57:19.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":41000,"derivative":{"exercise_price":11.34,"expiration_date":"2033-02-16","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000899243-23-005735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323005735/doc4.xml","form_type":"4"}},{"id":2002748,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-02-21T23:57:19.000Z","date":"2023-02-17","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":170115,"source":{"system":"sec-edgar","filing":"0000899243-23-005735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924323005735/doc4.xml","form_type":"4"}},{"id":2203707,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-07-21T20:30:37.000Z","date":"2022-07-19","kind":"sale","acquired":false,"shares":14958,"price":15.22,"value":227660.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":149615,"source":{"system":"sec-edgar","filing":"0000899243-22-026470","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322026470/doc4.xml","form_type":"4"}},{"id":2203706,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-07-21T20:30:37.000Z","date":"2022-07-18","kind":"sale","acquired":false,"shares":5042,"price":15.06,"value":75932.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.16. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":164573,"source":{"system":"sec-edgar","filing":"0000899243-22-026470","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322026470/doc4.xml","form_type":"4"}},{"id":2208401,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-07-12T20:14:27.000Z","date":"2022-07-11","kind":"sale","acquired":false,"shares":200,"price":13.85,"value":2770.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.84 to $13.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":169615,"source":{"system":"sec-edgar","filing":"0000899243-22-025971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322025971/doc4.xml","form_type":"4"}},{"id":2208400,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-07-12T20:14:27.000Z","date":"2022-07-11","kind":"sale","acquired":false,"shares":39800,"price":13.33,"value":530534.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.82 to $13.72. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":169815,"source":{"system":"sec-edgar","filing":"0000899243-22-025971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322025971/doc4.xml","form_type":"4"}},{"id":2393792,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:43:58.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":33000,"derivative":{"exercise_price":13.6,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0000899243-22-006413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322006413/doc4.xml","form_type":"4"}},{"id":2393791,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":65609,"kind":"person","name":"Savill Corrine","position":1,"cik":"0001837524","reported_name":"Savill Corrine","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-02-15T21:43:58.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":209615,"source":{"system":"sec-edgar","filing":"0000899243-22-006413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322006413/doc4.xml","form_type":"4"}}]}